Pediatric Nephrology

, Volume 29, Issue 8, pp 1373–1379

Impact of rituximab on height and weight in children with refractory steroid-dependent nephrotic syndrome

Original Article



Children with steroid-dependent nephrotic syndrome (SDNS) often suffer from serious adverse events, including growth retardation and obesity. Rituximab (RTX) is a promising therapeutic option to overcome steroid dependency. We have examined the impact of RTX on growth and obesity in children with SDNS.


Thirteen pediatric patients with SDNS who were refractory despite treatment with multiple immunosuppressive agents received RTX infusions. Mean follow-up was 2.3 years from the first administration of RTX. Improvement in the height and obesity indexes from prior to the initial RTX infusion through to the last visit was assessed.


After RTX, the number of relapses [2.8 (before RTX) vs. 0.8/year (after RTX); p = 0.0008] and the prednisolone dose (287.9 vs. 70.7 mg/kg/year, respectively; p = 0.0002) were significantly decreased. Marked improvement in the height standard deviation score (SDS) was achieved by ten of the 13 patients (77 %) [n = 13; −1.6 (before RTX) vs. −0.8 SDS (after RTX); p = 0.03]. Notably, the height SDS of seven of the eight patients whose height was less than average at the first RTX improved from −2.6 to −1.4 SDS with RTX therapy. At the same time, the obesity index of 12 of the 13 patients (92 %) significantly improved (n = 13; 16.9 vs. 3.1 %; p = 0.004).


Therapy with RTX may contribute to an improvement in the growth and obesity indexes in some patients suffering from severe side effects of steroids.


Nephrotic syndrome Rituximab Steroid Growth Obesity 


  1. 1.
    Bagga A, Mantan M (1995) Nephrotic syndrome in children. Indian J Med Res 122:13–28Google Scholar
  2. 2.
    Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr (1997) Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769–776PubMedGoogle Scholar
  3. 3.
    Sinha A, Hari P, Sharma PK, Gulati A, Kalaivani M, Mantan M, Dinda AK, Srivastava RN, Bagga A (2012) Disease course in steroid sensitive nephrotic syndrome. Indian Pediatr 49:881–887PubMedCrossRefGoogle Scholar
  4. 4.
    Rees L, Greene SA, Adlard P, Jones J, Haycock GB, Rigden SP, Preece M, Chantler C (1988) Growth and endocrine function in steroid sensitive nephrotic syndrome. Arch Dis Child 63:484–490PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Kashtan C, Melvin T, Kim Y (1988) Long-term follow-up of patients with steroid-dependent, minimal change nephrotic syndrome. Clin Nephrol 29:79–85PubMedGoogle Scholar
  6. 6.
    Emma F, Sesto A, Rizzoni G (2003) Long-term linear growth of children with severe steroid-responsive nephrotic syndrome. Pediatr Nephrol 18:783–788PubMedCrossRefGoogle Scholar
  7. 7.
    Kitamura M (1992) Growth retardation in children with frequent relapsing nephrotic syndrome on steroid–improvement of height velocity after administration of immunosuppressive agent Improvement of height velocity after administration of immunosuppressive agent. Nihon Jinzo Gakkai Shi 34:117–124PubMedGoogle Scholar
  8. 8.
    Leonard MB, Feldman HI, Shults J, Zemel BS, Foster BJ, Stallings VA (2004) Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 351:868–875PubMedCrossRefGoogle Scholar
  9. 9.
    Mitra S, Banerjee S (2011) The impact of pediatric nephrotic syndrome on families. Pediatr Nephrol 26:1235–1240PubMedCrossRefGoogle Scholar
  10. 10.
    Bagga A, Sinha A, Moudgil A (2007) Rituximab in patients with the steroid resistant nephrotic syndrome. N Engl J Med 356:2751–2752PubMedCrossRefGoogle Scholar
  11. 11.
    Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas E, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F (2008) Rituximab treatment for severe steroid-or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23:1269–1279PubMedCrossRefGoogle Scholar
  12. 12.
    Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K (2009) Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 24:1321–1328PubMedCrossRefGoogle Scholar
  13. 13.
    Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM (2011) Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6:1308–1315PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guérin V, Lapillonne H, Deschênes G, Ulinski T (2012) Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood-follow-up after CD19 recovery. Nephrol Dial Transplant 27:1083–1089PubMedCrossRefGoogle Scholar
  15. 15.
    Foote KD, Brocklebank JT, Meadow SR (1985) Height attainment in children with steroid-responsive nephrotic syndrome. Lancet 2:917–919PubMedCrossRefGoogle Scholar
  16. 16.
    Rüth EM, Kemper MJ, Leumann EP, Laube GF, Neuhaus TJ (2005) Children with steroid-sensitive nephrotic syndrome. Come of age: long-term outcome. J Pediatr 147:202–207PubMedCrossRefGoogle Scholar
  17. 17.
    Leroy V, Baudouin V, Alberti C, Guest G, Niaudet P, Loirat C, Deschenes G, Czernichow P, Simon D (2009) Growth in boys with idiopathic nephrotic syndrome on long-term cyclosporine and steroid treatment. Pediatr Nephrol 24:2393–2400PubMedCrossRefGoogle Scholar
  18. 18.
    Hung YT, Yang LY (2006) Follow-up of linear growth of body height in children with nephrotic syndrome. J Microbiol Immunol Infect 39:422–425PubMedGoogle Scholar
  19. 19.
    Elzouki AY, Jaiswal OP (1988) Long-term, small dose predonisone therapy in frequently relapsing nephritic syndrome of childhood. Effect on remission, statural growth, obesity, and infection rate. Clin Pediatr (Phila) 27:387–392CrossRefGoogle Scholar
  20. 20.
    Merritt RJ, Hack SL, Kalsch M, Olson D (1986) Corticosteroid therapy-induced obesity in children. Clin Pediatr (Phila) 25:149–152CrossRefGoogle Scholar
  21. 21.
    Foster BJ, Shults J, Zemel BS, Leonard MB (2004) Interactions between growth and body composition in children treated with high-dose chronic glucocorticoids. Am J Clin Nutr 80:1334–1341PubMedGoogle Scholar
  22. 22.
    Rüth EM, Landolt MA, Neuhaus TJ, Kemper MJ (2004) Health-related quality of life and psychosocial adjustment in steroid-sensitive nephrotic syndrome. J Pediatr 145:778–834PubMedCrossRefGoogle Scholar
  23. 23.
    Hall AS, Thorley G, Houtman PN (2003) The effects of corticosteroids on behavior in children with nephrotic syndrome. Pediatr Nephrol 18:1220–1223PubMedCrossRefGoogle Scholar
  24. 24.
    Mishra OP, Basu B, Upadhyay SK, Prasad R, Schaefer F (2010) Behavioural abnormalities in children with nephrotic syndrome. Nephrol Dial Transplant 25:2537–2541PubMedCrossRefGoogle Scholar
  25. 25.
    Neuhaus TJ, Langlois V, Licht C (2010) Behavioural abnormalities in children with nephrotic syndrome–an underappreciated complication of a standard treatment? Nephrol Dial Transplant 25:2397–2399PubMedCrossRefGoogle Scholar
  26. 26.
    Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Deschênes G (2009) Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 24:1753–1755PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2014

Authors and Affiliations

  • Mai Sato
    • 1
  • Shuichi Ito
    • 1
  • Masao Ogura
    • 1
  • Koichi Kamei
    • 1
  1. 1.Division of Nephrology and RheumatologyNational Center for Child Health and DevelopmentSetagaya-ku, TokyoJapan

Personalised recommendations